Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?

Abstract EN

Objective.

The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission.

Synovial Biomarkers.

High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their utility in clinical remission.

IIINys and Glc-Gal-PYD seem to be more specific to synovium, but more studies are required.

Cartilage Biomarkers.

Unbalance between cartilage break-down biomarkers (urinary CTX II and COMP) and cartilage formation biomarker (PIIANP) was described.

This unbalance is also associated with joint destruction and prognosis of destruction.

No data are available on patients in remission.

Bone Biomarkers.

RA activity is correlated with an increase of bone resorption markers such as CTX I, PYD, and TRACP 5b and a decrease of bone formation markers such as OC and BALP.

RA therapies seem to improve bone turnover in limiting bone resorption.

There is no study about bone marker utility in remission.

Conclusion.

Biomarkers seem to correlate with RA activity and progression.

They also could be used to manage RA therapies, but we need more data on RA remission to predict relapse.